ClinicalTrials.gg
CompletedNCT00002415Updated Jun 24, 2005

Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients

A Phase 2 interventional study of Tenofovir disoproxil fumarate in HIV Infections, sponsored by Gilead Sciences. Completed at 24 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.

Enrollment
34th of 94
175 · median 99
Phase 2
22 of 98
1 open now
Registered
1st of 98
by date
Lead sponsor
17 of 98
Gilead Sciences

Among the 98 studies testing tenofovir in HIV Infections, this one is the 34th largest by enrollment of the 94 interventional ones that give a count, is one of 22 in phase 2, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 98 studies testing tenofovir in HIV Infections is open now. Recruiting first, the newest first:

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing tenofovir in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to see if it is safe and effective to add PMPA Prodrug (a new anti-HIV drug) to an anti-HIV drug combination taken by patients who have taken anti-HIV drugs in the past. Genetic response will be studied.

Read the detailed description

Prior to study entry patients are stratified according to HIV-1 RNA level, CD4 cell count, and number of antiretroviral drugs. PMPA Prodrug or placebo is added to current antiretroviral regimens, and is administered in one of three dosing regimens. Patients randomized to receive placebo are eligible to receive open-label PMPA Prodrug for the remainder of the 48-week study period after at least 24 weeks post randomization.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Drug Therapy, Combination
  • Prodrugs
  • Anti-HIV Agents
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

You may be eligible for this study if you:

  • Are -positive.
  • Have an HIV count of 400 - 50,000 copies/ml.
  • Are expected to live for at least 1 year.
  • Have been taking the same anti-HIV drug combination (made up of no more than 3 anti-HIV drugs) for at least 8 weeks prior to study entry.
  • Are at least 18 years old.
  • Agree to use effective methods of during the study.

Exclusion criteria

Exclusion Criteria

You will not be eligible for this study if you:

  • Have taken medications for certain infections within 15 days prior to study entry.
  • Have a history of cancer, except Kaposi's sarcoma (KS) or skin cancer.
  • Develop a new AIDS-related condition within 30 days of study entry.
  • Have certain serious medical conditions, including severe nausea, vomiting, or other stomach problems that make you unable to take medications by mouth.
  • Have received a vaccine within 30 days prior to study entry.
  • Have taken certain medications, including those that may affect your kidneys.
  • Abuse alcohol or drugs.
  • Are pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
Double
Enrollment
175 participants
06

Study locations

24 sites
  • Univ of Alabama at Birmingham / 1917 Rsch Cln
    Birmingham, Alabama 35294, United States
  • McDowell Clinic
    Phoenix, Arizona 85016, United States
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • Tower Infectious Disease Med Ctr
    Los Angeles, California 90048, United States
  • UCSD Treatment Ctr
    San Diego, California 92103, United States
  • San Francisco Veterans Adm Med Cntr
    San Francisco, California 94121, United States
  • Harbor UCLA Med Ctr
    Torrance, California 90502, United States
  • Univ of Colorado Health Sciences Ctr
    Denver, Colorado 80262, United States
  • Hillsborough County Health Dept Special Care Ctr
    Tampa, Florida 33605, United States
  • AIDS Research Consortium of Atlanta Inc
    Atlanta, Georgia 30308, United States
  • Grady Mem Hosp
    Atlanta, Georgia 30308, United States
  • Private Practice / Thacker and Thompson
    Atlanta, Georgia 30324, United States
  • Northstar Med Clinic
    Chicago, Illinois 60657, United States
  • CRI New England
    Brookline, Massachusetts 02445, United States
  • Univ of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Beth Israel Med Ctr
    New York, New York 10003, United States
  • Cornell Clinical Trials Unit - Chelsea Clinic
    New York, New York 10011, United States
  • Univ Hosps of Cleveland
    Cleveland, Ohio 44106, United States
  • The Research and Education Group
    Portland, Oregon 97210, United States
  • Hershey Med Ctr
    Hershey, Pennsylvania 17033, United States
  • Anderson Clinical Research
    Pittsburgh, Pennsylvania 15213, United States
  • Roger Williams Med Ctr
    Providence, Rhode Island 02908, United States
  • Amelia Ct Clinic
    Dallas, Texas 75235, United States
  • Thomas Street Clinic
    Houston, Texas 77009, United States
07

References and documents

Publications

  • Miller MD, Margot NA, Schooley R, McGowan I. Baseline and week 48 final phenotypic analysis of HIV-1 from patients adding tenofovir disoproxil fumarate (TDF) therapy to background ART. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 441)
  • Schooley R, Myers R, Ruane R, Beall G, Lampiris H, McGowan I. A double-blind, placebo-controlled study of tenofovir disoproxil fumarate (TDF) for the treatment of HIV infection. 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sep (abstract no I302I)
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002415
Lead sponsor
Gilead Sciences
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 1999. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion